Anti-CD20-anti-Fc alpha RI bispecific monoclonal antibody

Drug Profile

Anti-CD20-anti-Fc alpha RI bispecific monoclonal antibody

Alternative Names: Bispecific monoclonal antibody anti-CD20-anti-Fc alpha RI-Medarex-Tenovus

Latest Information Update: 29 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medarex; Nonindustrial source; Tenovus
  • Developer Medarex
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors; Fc receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 29 Apr 1999 New profile
  • 29 Apr 1999 Preclinical development for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top